Compare MC & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | APGE |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.7B |
| IPO Year | 2014 | 2023 |
| Metric | MC | APGE |
|---|---|---|
| Price | $68.98 | $76.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $73.75 | ★ $99.44 |
| AVG Volume (30 Days) | 811.8K | ★ 970.7K |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | ★ 446.16 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $1,467,580,000.00 | N/A |
| Revenue This Year | $27.08 | N/A |
| Revenue Next Year | $17.26 | N/A |
| P/E Ratio | $21.69 | ★ N/A |
| Revenue Growth | ★ 51.19 | N/A |
| 52 Week Low | $47.00 | $26.20 |
| 52 Week High | $82.89 | $80.99 |
| Indicator | MC | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 59.51 |
| Support Level | $69.51 | $74.89 |
| Resistance Level | $71.78 | $78.34 |
| Average True Range (ATR) | 1.53 | 2.82 |
| MACD | -0.12 | -0.81 |
| Stochastic Oscillator | 11.83 | 34.68 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.